High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

By sjmartinez • April 29, 2025

Riddler SA, Moodie Z, Clark J, Yen C, Allen M, Furch BD, Lu H, Grant S, Mondal K, Anderson M, Maenza J, Lemos MP, Woodward Davis AS, Walsh SR, Sobieszczyk ME, Frank I, Goepfert P, Stephenson KE, Baden LR, Tieu HV, Keefer MC, McElrath MJ, Kublin JG, Corey L. High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). Ann Intern Med. 2025 Apr 29. doi: 10.7326/ANNALS-24-02701. Epub ahead of print. PMID: 40294415.

Tags: Infectious Diseases, Publications

Factors associated with cervical cancer screening: results from cross-sectional surveys in Kenya and Malawi

Moucheraud C, Chibaka S, Golub G, Kalande P, Makwaya A, Ochieng E, Ogutu V, Phiri K, Phiri S, Hoffman RM. Factors associated with cervical cancer[...]

Risks for sudden cardiac and undetermined cause of death among people with HIV in the reprieve primary cardiovascular prevention trial

deFilippi C, Awwad A, Bloomfield GS, Weir IR, Ribaudo H, Zanni MV, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Diggs MR, Chu SM, Paradis K, MacArthur[...]

rLVS(delta) capB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli

Jia Q, Bowen RA, Masleša-Galić S, Horwitz MA. rLVS ΔcapB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal[...]